Gland Pharma Limited (GLAND) — Cash Flow-to-Debt Ratio
Gland Pharma Limited (GLAND) has a Cash Flow-to-Debt Ratio of 0.27x as of September 2025, meaning its operating cash flow of Rs5.93 Billion could theoretically repay 0% of its total liabilities (Rs22.37 Billion) in one year. Check Gland Pharma Limited (GLAND) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Gland Pharma Limited Cash Flow-to-Debt Ratio (2017–2026)
Historical debt coverage capacity for Gland Pharma Limited across 10 annual periods. Also explore Gland Pharma Limited asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Gland Pharma Limited (2017–2026)
Year-by-year debt coverage analysis for Gland Pharma Limited. For market capitalisation and broader financial context, see Gland Pharma Limited market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (INR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | 0.57x | Rs12.31 Billion | Rs21.53 Billion | ▲ +29.7% |
| 2025 | 0.44x | Rs9.15 Billion | Rs20.74 Billion | ▼ -14.3% |
| 2024 | 0.51x | Rs9.97 Billion | Rs19.37 Billion | ▲ +15.7% |
| 2023 | 0.44x | Rs3.64 Billion | Rs8.19 Billion | ▼ -62.0% |
| 2022 | 1.17x | Rs7.91 Billion | Rs6.76 Billion | ▲ +14.6% |
| 2021 | 1.02x | Rs6.05 Billion | Rs5.93 Billion | ▼ -36.0% |
| 2020 | 1.59x | Rs7.01 Billion | Rs4.40 Billion | ▲ +469.1% |
| 2019 | 0.28x | Rs1.85 Billion | Rs6.62 Billion | ▼ -28.1% |
| 2018 | 0.39x | Rs2.02 Billion | Rs5.19 Billion | ▼ -68.6% |
| 2017 | 1.24x | Rs4.76 Billion | Rs3.84 Billion | — |